Synairgen PLC's (LON:SNG) CEO Richard Marsden caught up with Proactive London's Andrew Scott after announcing that the trial of its SNG001 interferon-beta treatment will be extended to coronavirus patients in the home environment. He says the idea behind the move is to dose patients with the treatment earlier in the infection cycle before severe lower respiratory tract symptoms develop.
Synairgen CEO details expansion of key coronavirus trial to patients in home
Quick facts: Synairgen PLC
Price: 174 GBX
Market Cap: £347.85 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE